BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Merck & Co is set to exit the genomic services and cancer diagnostics provider in an acquisition by Bio-Techne potentially sized at $320m.

Telus’ corporate venturing unit has led a $23.7m round for the Canadian online pharmacy as it seeks to take its coverage nationwide.

Inovio Pharmaceuticals spinoff Geneos Therapeutics will put the proceeds from the series A1 round towards advancing its liver cancer vaccine candidate.

Exploiting UChicago research, Reflexion is eyeing an expansion in Asia after receiving $40m in additional series D funding to bring the round to $150m.

Echo Health Ventures and Humana have returned to back the healthcare delivery provider’s series D round, which valued it at $1.7bn.

The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.

An unnamed care provider has added $20m to the $80m the software-based therapeutics developer received from investors including Novartis and SoftBank in December.

Access Biotechnology and returning investor Eli Lilly were among the participants in a series B round for the RNA-based drug developer.

Susquehanna International Group looks set to exit the microbiome therapeutics developer, which has filed to raise up to $100m in its initial public offering.